Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587055 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1CYP2C19 | |
| SCHEMBL1819248 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1CYP2C19 | |
| SCHEMBL1972076 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1CYP2C19 | |
| SCHEMBL1818678 | 0.84 | CYP1A2 (0.52) | CYP1A2SIGMAR1CD274PDCD1SPHK1 | |
| SCHEMBL3148367 | 0.84 | NPBWR1 (0.53) | CYP1A2SIGMAR1CD274PDCD1SPHK1 | |
| SCHEMBL1815987 | 0.84 | NPBWR1 (0.53) | CYP1A2SIGMAR1CD274PDCD1SPHK1 | |
| SCHEMBL1817630 | 0.84 | MAOA (0.60) | CYP1A2SIGMAR1CD274PDCD1SPHK1 | |
| SCHEMBL2029190 | 0.84 | CD274 (0.54) | CYP1A2CD274PDCD1MEN1KMT2A | |
| SCHEMBL2029480 | 0.84 | CYP1A2 (0.52) | CYP1A2SIGMAR1CD274PDCD1SPHK1 | |
| SCHEMBL2029008 | 0.84 | MAOA (0.60) | CYP1A2SIGMAR1CD274PDCD1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 1575/4885SIGMAR1 4679/4885CD274 2122/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885SIGMAR1 4687/4885CD274 2533/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 2416/4885SIGMAR1 4687/4885CD274 2533/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 1625/4885SIGMAR1 4674/4885CD274 2205/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885SIGMAR1 4687/4885CD274 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.